The results of KEGG and GO enrichment analysis show that the therapeutic effect of the XHP in pancreatic cancer is mainly involved in the MAPK pathway, the NF-κB pathway, IL17 signaling, pathways in cancer, etc. These results are in agreement with other results suggesting that Integrin/EGFR-ERK/MAPK signaling promotes the growth and metastasis of pancreatic tumors [36]. The gene discussed is IL17A; the disease is pancreatic neoplasm.